Minnesota's 48-hour rule changes

The state currently has 48 hours to move a mentally ill, civilly committed individual out of a jail and into a mental health treatment setting, but several stakeholders are worried about additional requirements to the rule.

Promising trial for Alzheimer's treatment

Eli Lilly last week announced the results of a Phase 3 trial on its experimental drug called Donanemab. The latest drug trial in a new class of Alzheimer’s drugs gives researchers and advocates renewed hope of slowing the progression of the brain disease.

Full interview: Dr. Ronald Petersen

Eli Lilly last week announced the results of a Phase 3 trial on its experimental drug called Donanemab. The drug attacks the amyloid proteins in the brain that lead to a buildup of plaque between neurons that weakens the ability of the neurons to communicate. The growth of these plaques along with tau protein strands leads to Alzheimer’s disease and dementia that robs a person of their memory, and eventually their bodily functions leading to death. Tim Blotz spoke with Dr. Ronald Petersen about the drug.